Cargando…

VGF Peptide Profiles in Type 2 Diabetic Patients’ Plasma and in Obese Mice

To address the possible involvement of VGF peptides in obesity and diabetes, we studied type 2 diabetes (T2D) and obese patients, and high-fat diet induced obese mice. Two VGF peptides (NAPP-19 and QQET-30) were identified in human plasma by HPLC-ESI-MS. The VGF C-terminus, the above two cleaved pep...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Amato, Filomena, Noli, Barbara, Angioni, Laura, Cossu, Efisio, Incani, Michela, Messana, Irene, Manconi, Barbara, Solinas, Paola, Isola, Raffaella, Mariotti, Stefano, Ferri, Gian-Luca, Cocco, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643017/
https://www.ncbi.nlm.nih.gov/pubmed/26562304
http://dx.doi.org/10.1371/journal.pone.0142333
_version_ 1782400452066803712
author D’Amato, Filomena
Noli, Barbara
Angioni, Laura
Cossu, Efisio
Incani, Michela
Messana, Irene
Manconi, Barbara
Solinas, Paola
Isola, Raffaella
Mariotti, Stefano
Ferri, Gian-Luca
Cocco, Cristina
author_facet D’Amato, Filomena
Noli, Barbara
Angioni, Laura
Cossu, Efisio
Incani, Michela
Messana, Irene
Manconi, Barbara
Solinas, Paola
Isola, Raffaella
Mariotti, Stefano
Ferri, Gian-Luca
Cocco, Cristina
author_sort D’Amato, Filomena
collection PubMed
description To address the possible involvement of VGF peptides in obesity and diabetes, we studied type 2 diabetes (T2D) and obese patients, and high-fat diet induced obese mice. Two VGF peptides (NAPP-19 and QQET-30) were identified in human plasma by HPLC-ESI-MS. The VGF C-terminus, the above two cleaved peptides, and the TLQP-21 related peptide/s were studied using ELISA and immunohistochemistry. In euglycemic patients, plasma NAPPE and TLQP like peptides were significantly reduced with obesity (74±10 vs. 167±28, and 92±10 vs. 191±19 pmol/ml, mean+SEM, n = 10 and 6, obese vs. normal BMI, respectively, p<0.03). Upon a standard glucose load, a distinct response was shown for VGF C-terminus, TLQP and QQET-like (ERVW immunoreactive) peptides in euglycemic normal BMI patients, but was virtually abolished in euglycemic obese, and in T2D patients independently of BMI. High-fat diet induced obese mice showed reduced plasma VGF C-terminus, NAPPE and QQET-like (ERVW) peptide/s (3±0.2 vs. 4.6±0.3, 22±3.5 vs. 34±1.3, and 48±7 vs. 100±7 pmol/ml, mean+SEM, n = 8/group, obese vs. slim, respectively, p<0.03), with a loss of the response to glucose for all VGF peptides studied. In immunohistochemistry, TLQP and/or VGF C-terminus antibodies labelled VGF containing perikarya in mouse celiac ganglia, pancreatic islet cells and thin beaded nerve fibres in brown adipose tissues, with fewer in white adipose tissue. Upon the glucose load, tyrosine hydroxylase and VGF C-terminus immunoreactive axons became apparent in pancreatic islets of slim animals, but not in obese animals. Alltogether, a significant loss of VGF peptide immunoreactivity and/or their response to glucose was demonstrated in obese patients, with or without T2D, in parallel with a similar loss in high-fat diet induced obese mice. An involvement of VGF in metabolic regulations, including those of brown and/or white adipose tissues is underlined, and may point out specific VGF peptides as potential targets for diagnosis and/or treatment.
format Online
Article
Text
id pubmed-4643017
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-46430172015-11-18 VGF Peptide Profiles in Type 2 Diabetic Patients’ Plasma and in Obese Mice D’Amato, Filomena Noli, Barbara Angioni, Laura Cossu, Efisio Incani, Michela Messana, Irene Manconi, Barbara Solinas, Paola Isola, Raffaella Mariotti, Stefano Ferri, Gian-Luca Cocco, Cristina PLoS One Research Article To address the possible involvement of VGF peptides in obesity and diabetes, we studied type 2 diabetes (T2D) and obese patients, and high-fat diet induced obese mice. Two VGF peptides (NAPP-19 and QQET-30) were identified in human plasma by HPLC-ESI-MS. The VGF C-terminus, the above two cleaved peptides, and the TLQP-21 related peptide/s were studied using ELISA and immunohistochemistry. In euglycemic patients, plasma NAPPE and TLQP like peptides were significantly reduced with obesity (74±10 vs. 167±28, and 92±10 vs. 191±19 pmol/ml, mean+SEM, n = 10 and 6, obese vs. normal BMI, respectively, p<0.03). Upon a standard glucose load, a distinct response was shown for VGF C-terminus, TLQP and QQET-like (ERVW immunoreactive) peptides in euglycemic normal BMI patients, but was virtually abolished in euglycemic obese, and in T2D patients independently of BMI. High-fat diet induced obese mice showed reduced plasma VGF C-terminus, NAPPE and QQET-like (ERVW) peptide/s (3±0.2 vs. 4.6±0.3, 22±3.5 vs. 34±1.3, and 48±7 vs. 100±7 pmol/ml, mean+SEM, n = 8/group, obese vs. slim, respectively, p<0.03), with a loss of the response to glucose for all VGF peptides studied. In immunohistochemistry, TLQP and/or VGF C-terminus antibodies labelled VGF containing perikarya in mouse celiac ganglia, pancreatic islet cells and thin beaded nerve fibres in brown adipose tissues, with fewer in white adipose tissue. Upon the glucose load, tyrosine hydroxylase and VGF C-terminus immunoreactive axons became apparent in pancreatic islets of slim animals, but not in obese animals. Alltogether, a significant loss of VGF peptide immunoreactivity and/or their response to glucose was demonstrated in obese patients, with or without T2D, in parallel with a similar loss in high-fat diet induced obese mice. An involvement of VGF in metabolic regulations, including those of brown and/or white adipose tissues is underlined, and may point out specific VGF peptides as potential targets for diagnosis and/or treatment. Public Library of Science 2015-11-12 /pmc/articles/PMC4643017/ /pubmed/26562304 http://dx.doi.org/10.1371/journal.pone.0142333 Text en © 2015 D’Amato et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
D’Amato, Filomena
Noli, Barbara
Angioni, Laura
Cossu, Efisio
Incani, Michela
Messana, Irene
Manconi, Barbara
Solinas, Paola
Isola, Raffaella
Mariotti, Stefano
Ferri, Gian-Luca
Cocco, Cristina
VGF Peptide Profiles in Type 2 Diabetic Patients’ Plasma and in Obese Mice
title VGF Peptide Profiles in Type 2 Diabetic Patients’ Plasma and in Obese Mice
title_full VGF Peptide Profiles in Type 2 Diabetic Patients’ Plasma and in Obese Mice
title_fullStr VGF Peptide Profiles in Type 2 Diabetic Patients’ Plasma and in Obese Mice
title_full_unstemmed VGF Peptide Profiles in Type 2 Diabetic Patients’ Plasma and in Obese Mice
title_short VGF Peptide Profiles in Type 2 Diabetic Patients’ Plasma and in Obese Mice
title_sort vgf peptide profiles in type 2 diabetic patients’ plasma and in obese mice
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4643017/
https://www.ncbi.nlm.nih.gov/pubmed/26562304
http://dx.doi.org/10.1371/journal.pone.0142333
work_keys_str_mv AT damatofilomena vgfpeptideprofilesintype2diabeticpatientsplasmaandinobesemice
AT nolibarbara vgfpeptideprofilesintype2diabeticpatientsplasmaandinobesemice
AT angionilaura vgfpeptideprofilesintype2diabeticpatientsplasmaandinobesemice
AT cossuefisio vgfpeptideprofilesintype2diabeticpatientsplasmaandinobesemice
AT incanimichela vgfpeptideprofilesintype2diabeticpatientsplasmaandinobesemice
AT messanairene vgfpeptideprofilesintype2diabeticpatientsplasmaandinobesemice
AT manconibarbara vgfpeptideprofilesintype2diabeticpatientsplasmaandinobesemice
AT solinaspaola vgfpeptideprofilesintype2diabeticpatientsplasmaandinobesemice
AT isolaraffaella vgfpeptideprofilesintype2diabeticpatientsplasmaandinobesemice
AT mariottistefano vgfpeptideprofilesintype2diabeticpatientsplasmaandinobesemice
AT ferrigianluca vgfpeptideprofilesintype2diabeticpatientsplasmaandinobesemice
AT coccocristina vgfpeptideprofilesintype2diabeticpatientsplasmaandinobesemice